The emergence of the cannabis industry has led to the creation of sub-industries within it and this has created numerous opportunities for investors.
One sub-industry we find to be very attractive is biotech and this is due to the potential development of numerous billion dollar products.
The potential medical benefits of cannabis can no longer be ignored as agencies like the National Cancer Institute (NCI) continue to recognize its potential. In 2015, the NCI updated its website to include various studies that reveal how cannabis may inhibit tumor growth by killing cells.
Betting on Biotech
Although the biotech industry offers a lot of opportunity, it presents even more risk. When we look at biotech investment opportunities, we look for companies that possess a competitive or unique advantage over their peers.
Last week, one of the biotech companies we have been monitoring closely, Nemus Bioscience (NMUS), announced that it will be advancing the development of a human-dosage suppository formulation of NB1222 with Catalent Pharma Solutions. The product candidate is the proprietary prodrug of tetrahydrocannabinol (THC).
NB1222 has been synthetically manufactured and is being developed to treat and manage chemotherapy-induced nausea and vomiting (CINV). Nemus also plans on advancing this prodrug into formulation activity for the glaucoma indication using its NB1111 candidate molecule.
Today, Nemus signed a development agreement with United Kingdom-based Nanomerics to develop a topical ocular formulation of tetrahydrocannabinol-valine-hemisuccinate (THCVHS), the prodrug of THC, the active component of Nemus drug candidate NB1111 being developed for glaucoma.
The goal of the agreement is to conduct initial studies assessing the preparation of clinical-grade eye drops using the patented Molecular Envelope Technology (MET) developed by Nanomerics.
According to the agreement, work will commence on a future date determined by Nemus. The date is expected to be related with its development plans and corporate objectives.
Nemus Bioscience CEO Brian Murphy said, “Should we find success in formulating NB1111 using Nanomerics’ MET, we could also examine its application using our proprietary Nemus ophthalmic analogue of CBD (NB2222). Our company objective is to establish strategic partnerships utilizing a diverse cannabinoid-based ocular platform to address multiple types of eye disease.”
A Stock to Watch
Nemus Bioscience is an interesting company to watch due to its valuation, product pipeline, and its strategic partnership with the University of Mississippi. The university has been the sole provider of cannabis for medical research through a partnership with the National Institutes of Health since 1968.
We are favorable on this update as it shows further execution by Nemus. The company’s strategic relationship with Federal agencies makes it an attractive opportunity for investors and a stock to watch.
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
1 comment
What can we do to insure that the NIDA is allowing researchers and scientist have quality cannabis to test?